Reversal of obesity and insulin resistance by a non- peptidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  He, Min ^a,b   Su, Haoran ^a,d   Gao, Weiwei ^a   Johansson, Stina M ^a,e   Liu, Qing ^a,b   Wu, Xiaoyan ^a,b   Liao, Jiayu ^a,f   Young, Andrew A ^a,g   Bartfai, Tamas ^c   Wang, Ming Wei ^a,b,c  

^a National Center for Drug Screening   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f University of California Riverside ^*  (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BOC5; CHOLESTEROL; FATTY ACID; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HORMONE RECEPTOR STIMULATING AGENT; LEPTIN; LOW DENSITY LIPOPROTEIN; NORADRENALIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BOC5 COMPOUND; CYCLOBUTANE DERIVATIVE; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; BODY MASS; CELL STRUCTURE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; LIPOLYSIS; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; TREATMENT DURATION; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; C57BL MOUSE; CYTOLOGY; DIET; DISEASE MODEL; DRUG POTENTIATION; HOMEOSTASIS; METABOLISM; MOUSE MUTANT; ORGAN SIZE;

ANIMALIA; MUS;

ADIPOCYTES; ANIMALS; BODY MASS INDEX; BODY WEIGHT; CYCLOBUTANES; DIET; DISEASE MODELS, ANIMAL; GLUCOSE; HOMEOSTASIS; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; OBESITY; ORGAN SIZE; RECEPTORS, GLUCAGON;

EID: 78649960483     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014205     Document Type: Article

References (97)

1. Gale SM, Castracane VD, Mantzoros CS (2004) Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. J Nutr 134: 295-298.
2. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, et al. (2004) Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291: 2847-2850.
3. Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106: 473-481.
4. Kopelman PG (2000) Obesity as a medical problem. Nature 404: 635-643.
5. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, et al. (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76-79.
6. Bray GA (2004) Medical consequences of obesity. J Clin Endocrinol Metab 89: 2583-2589.
7. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, et al. (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30: 162-172.
8. Stone NJ, Kushner R (2000) Effects of dietary modification and treatment of obesity. Emphasis on improving vascular outcomes. Med Clin North Am 84: 95-122.
9. Wadden TA, Foster GD (2000) Behavioral treatment of obesity. Med Clin North Am 84: 441-461.
10. Bays HE (2004) Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 12: 1197-1211.
11. Badman MK, Flier JS (2005) The gut and energy balance: visceral allies in the obesity wars. Science 307: 1909-1914.
12. Wren AM (2008) Gut and hormones and obesity. Front Horm Res 36: 165-181.
13. Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520.
14. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, et al. (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126.
15. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, et al. (1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferentmediated central mechanisms. Am J Physiol 273: G920-927.
16. Meier JJ, Nauck MA (2004) The potential role of glucagon-like peptide 1 in diabetes. Curr Opin Investig Drugs 5: 402-410.
17. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, et al. (2001) Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 53: 260-267.
18. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, et al. (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29: 139-153.
19. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, et al. (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26- week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39-47.
20. Colagiuri S (2010) Diabesity: therapeutic options. Diabetes Obes Metab 12: 463-473.
21. Ahren B, Winzell MS, Wierup N, Sundler F, Burkey B, et al. (2007) DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept 143: 97-103.
22. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, et al. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30: 1487-1493.
23. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, et al. (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56: 8-15.
24. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, et al. (2007) Smallmolecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 104: 937-942.
25. Teng M, Johnson MD, Thomas C, Kiel D, Lakis JN, et al. (2007) Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorg Med Chem Lett 17: 5472-5478.
26. Chen D, Liao J, Li N, Zhou C, Liu Q, et al. (2007) A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci USA 104: 943-948.
27. Su H, He M, Li H, Liu Q, Wang J, et al. (2008) Boc5, a non-peptidic glucagonlike peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One 3: e2892.
28. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, et al. (1995) Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44: 645-651.
29. West DB, Boozer CN, Moody DL, Atkinson RL (1992) Dietary obesity in nine inbred mouse strains. Am J Physiol 262: R1025-1032.
30. Winzell MS, Ahren B (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53 Suppl 3: S215-219.
31. Carmen GY, Víctor SM (2006) Signalling mechanisms regulating lipolysis. Cellular signalling 18: 401-408.
32. Olleros ML, Martin ML, Vesin D, Fotio AL, Santiago-Raber ML, et al. (2008) Fat diet and alcohol-induced steatohepatitis after LPS challenge in mice: role of bioactive TNF and Th1 type cytokines. Cytokine 44: 118-125.
33. Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setala K, et al. (1993) Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest 91: 1665-1671.
34. Wolf G (1996) High-fat, high-cholesterol diet raises plasma HDL cholesterol: studies on the mechanism of this effect. Nutr Rev 54: 34-35.
35. Field BC, Wren AM, Cooke D, Bloom SR (2008) Gut hormones as potential new targets for appetite regulation and the treatment of obesity. Drugs 68: 147-163.
36. Parekh PI, Petro AE, Tiller JM, Feinglos MN, Surwit RS (1998) Reversal of dietinduced obesity and diabetes in C57BL/6J mice. Metabolism 47: 1089-1096.
37. Petro AE, Cotter J, Cooper DA, Peters JC, Surwit SJ, et al. (2004) Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 53: 454-457.
38. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN (1988) Dietinduced type II diabetes in C57BL/6J mice. Diabetes 37: 1163-1167.
39. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, et al. (1998) Life without white fat: a transgenic mouse. Genes Dev 12: 3168-3181.
40. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, et al. (1998) Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12: 3182-3194.
41. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, et al. (2006) Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30: 1332-1340.
42. Hui H, Farilla L, Merkel P, Perfetti R (2002) The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol 146: 863-869.
43. Dietz WH, Robinson TN (1998) Use of the body mass index (BMI) as a measure of overweight in children and adolescents. J Pediatr 132: 191-193.
44. Gavrilova O, Leon LR, Marcus-Samuels B, Mason MM, Castle AL, et al. (1999) Torpor in mice is induced by both leptin-dependent and -independent mechanisms. Proc Natl Acad Sci USA 96: 14623-14628.
45. Severinsen T, Munch IC (1999) Body core temperature during food restriction in rats. Acta Physiol Scand 165: 299-305.
46. Spiegelman BM, Flier JS (1996) Adipogenesis and obesity: rounding out the big picture. Cell 87: 377-389.
47. Lowell BB, Spiegelman BM (2000) Towards a molecular understanding of adaptive thermogenesis. Nature 404: 652-660.
48. Spiegelman BM, Flier JS (2001) Obesity and the regulation of energy balance. Cell 104: 531-543.
49. Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892: 146-154.
50. Rajala MW, Scherer PE (2003) Minireview: The adipocyte: at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144: 3765-3773.
51. Tiessen RG, Castaigne JP, Dreyfus JF, Nemansky M, Kruizinga HH, et al. (2008) Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int J Clin Pharmacol Ther 46: 443-452.
52. Large V, Peroni O, Letexier D, Ray H, Beylot M (2004) Metabolism of lipids in human white adipocyte. Diabetes Metab 30: 294-309.
53. Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H (2003) Increased glucose uptake promotes oxidative stress and PKC-δ activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab 285: E295-302.
54. Crowe S, Turpin SM, Ke F, Kemp BE, Watt MJ (2008) Metabolic remodeling in adipocytes promotes ciliary neurotrophic factor-mediated fat loss in obesity. Endocrinology 149: 2546-2556.
55. Sancho V, Trigo MV, Martin-Duce A, Gonz Lez N, Acitores A, et al. (2006) Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects. Int J Mol Med 17: 1133-1137.
56. Langin D, Dicker A, Tavernier G, Hoffstedt J, Mairal A, et al. (2005) Adipocyte lipases and defect of lipolysis in human obesity. Diabetes 54: 3190-3197.
57. Reynisdottir S, Wahrenberg H, Carlstrom K, Rossner S, Arner P (1994) Catecholamine resistance in fat cells of women with upper-body obesity due to decreased expression of beta 2-adrenoceptors. Diabetologia 37: 428-435.
58. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194-206.
59. Arner P (2005) Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 19: 471-482.
60. Osuga J, Ishibashi S, Oka T, Yagyu H, Tozawa R, et al. (2000) Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc Natl Acad Sci USA 97: 787-792.
61. Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, Diaz-Miguel M, Valverde I (2001) Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 33: 73-77.
62. Gonzalez N, Acitores A, Sancho V, Valverde I, Villanueva-Penacarrillo ML (2005) Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126: 203-211.
63. Sancho V, Trigo MV, Gonzalez N, Valverde I, Malaisse WJ, et al. (2005) Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. J Mol Endocrinol 35: 27-38.
64. Merida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I (1993) Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 77: 1654-1657.
65. Prentki M, Nolan CJ (2006) Islet β cell failure in type 2 diabetes. J Clin Invest 116: 1802-1812.
66. Inuwa IM, El Mardi AS (2005) Correlation between volume fraction and volume-weighted mean volume, and between total number and total mass of islets in post-weaning and young Wistar rats. J Anat 206: 185-192.
67. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, et al. (2005) Exenatide (exendin-4) improves insulin sensitivity and β-cell mass in insulinresistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146: 2069-2076.
68. Li LX, MacDonald PE, Ahn DS, Oudit GY, Backx PH, et al. (2006) Role of phosphatidylinositol 3-kinase γ in the β-cell: interactions with glucagon-like peptide-1. Endocrinology 147: 3318-3325.
69. MacGregor RR, Williams SJ, Tong PY, Kover K, Moore WV, et al. (2006) Small rat islets are superior to large islets in in vitro function and in transplantation outcomes. Am J Physiol Endocrinol Metab 290: E771-779.
70. Mizuno A, Kuwajima M, Ishida K, Noma Y, Murakami T, et al. (1997) Extrapancreatic action of truncated glucagon-like peptide-I in Otsuka Long- Evans Tokushima Fatty rats, an animal model for non-insulin-dependent diabetes mellitus. Metabolism 46: 745-749.
71. Young A (2002) Glucagon-like peptide-1, exendin and insulin sensitivity. In: Hansen B, Shafrir E, eds. Insulin Resistance and Insulin Resistance Syndrome. New York: Taylor and Francis, London. pp 235-262.
72. Berg AH, Combs TP, Scherer PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13: 84-89.
73. Pajvani UB, Scherer PE (2003) Adiponectin: systemic contributor to insulin sensitivity. Curr Diab Rep 3: 207-213.
74. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, et al. (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med 8: 1288-1295.
75. Yki-Jarvinen H, Westerbacka J (2005) The fatty liver and insulin resistance. Curr Mol Med 5: 287-295.
76. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA (2006) Exendin-4, a glucagon-like peptide-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43: 173-181.
77. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, et al. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24: 275-286.
78. Goodpaster BH, He J, Watkins S, Kelley DE (2001) Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 86: 5755-5761.
79. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, et al. (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49: 749-758.
80. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-176.
81. Schreyer SA, Wilson DL, LeBoeuf RC (1998) C57BL/6 mice fed high fat diets as models for diabetes-accelerated atherosclerosis. Atherosclerosis 136: 17-24.
82. Maggio CA, Pi-Sunyer FX (2003) Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 32: 805-822.
83. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 3-10.
84. Zimmermann R, Haemmerle G, Wagner EM, Strauss JG, Kratky D, et al. (2003) Decreased fatty acid esterification compensates for the reduced lipolytic activity in hormone-sensitive lipase-deficient white adipose tissue. J Lipid Res 44: 2089-2099.
85. Johnson PR, Hirsch J (1972) Cellularity of adipose depots in six strains of genetically obese mice. J Lipid Res 13: 2-11.
86. Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, et al. (1989) Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 68: 374-378.
87. Murphy KG, Bloom SR (2007) Nonpeptidic glucagon-like peptide 1 receptor agonists: a magic bullet for diabetes? Proc Natl Acad Sci USA 104: 689-690.
88. Johansson SM, Yang JN, Lindgren E, Fredholm BB (2007) Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid. Acta Physiol (Oxf) 190: 87-96.
89. Rodbell M (1964) Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239: 375-380.
90. Fredholm BB (1985) Methods used to study the involvement of adenosine in the regulation of lipolysis. In: Paton DM, ed. Methods in Pharmacology. New YorkNY: Meredith Corp. pp 337-358.
91. Arner P, Engfeldt P (1987) Fasting-mediated alteration studies in insulin action on lipolysis and lipogenesis in obese women. Am J Physiol 253: E193-201.
92. Johansson SM, Lindgren E, Yang JN, Herling AW, Fredholm BB (2008) Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue - Interactions with insulin. Eur J Pharmacol 597: 92-101.
93. Laurell S, Tibbling G (1966) An enzymatic fluorometric micromethod for the determination of glycerol. Clin Chim Acta 13: 317-322.
94. Kobayashi-Hattori K, Mogi A, Matsumoto Y, Takita T (2005) Effect of caffeine on the body fat and lipid metabolism of rats fed on a high-fat diet. Biosci Biotechnol Biochem 69: 2219-2223.
95. Harris RB, Martin RJ (1984) Specific depletion of body fat in parabiotic partners of tube-fed obese rats. Am J Physiol 247: 380-386.
96. Kloting N, Koch L, Wunderlich T, Kern M, Ruschke K, et al. (2008) Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. Diabetes 57: 2074-2082.
97. Folch J, Lees M, Stanley GHS (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.